Article Text


Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon.
  1. J G Kingham,
  2. N K Ganguly,
  3. Z D Shaari,
  4. R Mendelson,
  5. M J McGuire,
  6. S J Holgate,
  7. T Cartwright,
  8. G M Scott,
  9. B M Richards,
  10. R Wright


    Two patients with HBsAg positive chronic active hepatitis have been treated with human fibroblast interferon 10(7) units daily for two weeks. Before treatment, both patients had high levels of hepatitis B surface antigen, core antibody, and DNA-binding antibody in the blood and one patient had a fourfold rise in serum AST. During treatment there was a striking fall in the core antibody titre and also in the DNA-binding antibody, which has been maintained for several months subsequently; in one patient the initially high AST level fell to normal. No significant adverse effects occurred, and these observations should encourage further trials of fibroblasts interferon in hepatitis B.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.